- Home
- APVO vs OGEN Comparison
APVO vs OGEN Comparison
Compare APVO & OGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APVO
- OGEN
- Stock Information
- Founded
- APVO 2016
- OGEN 1996
- Country
- APVO United States
- OGEN United States
- Employees
- APVO N/A
- OGEN N/A
- Industry
- APVO Biotechnology: Pharmaceutical Preparations
- OGEN Biotechnology: Pharmaceutical Preparations
- Sector
- APVO Health Care
- OGEN Health Care
- Exchange
- APVO Nasdaq
- OGEN Nasdaq
- Market Cap
- APVO 4.4M
- OGEN 4.5M
- IPO Year
- APVO N/A
- OGEN N/A
- Fundamental
- Price
- APVO $4.50
- OGEN $0.34
- Analyst Decision
- APVO Strong Buy
- OGEN
- Analyst Count
- APVO 1
- OGEN 0
- Target Price
- APVO $296.00
- OGEN N/A
- AVG Volume (30 Days)
- APVO 485.4K
- OGEN 269.0K
- Earning Date
- APVO 11-07-2024
- OGEN 11-13-2024
- Dividend Yield
- APVO N/A
- OGEN N/A
- EPS Growth
- APVO N/A
- OGEN N/A
- EPS
- APVO N/A
- OGEN N/A
- Revenue
- APVO N/A
- OGEN N/A
- Revenue This Year
- APVO N/A
- OGEN N/A
- Revenue Next Year
- APVO N/A
- OGEN N/A
- P/E Ratio
- APVO N/A
- OGEN N/A
- Revenue Growth
- APVO N/A
- OGEN N/A
- 52 Week Low
- APVO $3.65
- OGEN $0.25
- 52 Week High
- APVO $399.60
- OGEN $7.74
- Technical
- Relative Strength Index (RSI)
- APVO 35.34
- OGEN 49.33
- Support Level
- APVO $3.65
- OGEN $0.32
- Resistance Level
- APVO $4.78
- OGEN $0.38
- Average True Range (ATR)
- APVO 1.95
- OGEN 0.03
- MACD
- APVO -0.70
- OGEN 0.00
- Stochastic Oscillator
- APVO 7.55
- OGEN 38.89
About APVO Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc is a clinical-stage, research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidate, APVO436, and preclinical candidates, ALG.APV-527 and APVO603, were developed using ADAPTIR modular protein technology platform. The versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.
About OGEN Oragenics Inc.
Oragenics Inc is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. The company's lead product ONP-002 is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification.